{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:42:02Z","timestamp":1790379722288,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100020320","name":"IReSP","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.therap.2024.04.002","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T16:01:57Z","timestamp":1713456117000},"page":"646-654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["GPs\u2019 practices when prescribing buprenorphine in primary care: A survey among the Sentinelles network"],"prefix":"10.1016","volume":"79","author":[{"given":"Barbara","family":"L\u00e9pine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Debin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Dassieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Gimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Palmaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Pont\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Swital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Blanchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Dupouy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2024.04.002_bib0155","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Bon usage des m\u00e9dicaments opio\u00efdes: antalgie, pr\u00e9vention et prise en charge du trouble de l\u2019usage et des surdoses. 2022. https:\/\/www.has-sante.fr\/jcms\/p_3215131\/fr\/bon-usage-des-medicaments-opioides-antalgie-prevention-et-prise-en-charge-du-trouble-de-l-usage-et-des-surdoses. [Accessed 11 April 2024]."},{"key":"10.1016\/j.therap.2024.04.002_bib0160","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2019: Trends and Developments. Luxembourg: Publications Office of the European Union. 2019. https:\/\/www.emcdda.europa.eu\/publications\/edr\/trends-developments\/2019_en. [Accessed 11 April 2024]."},{"key":"10.1016\/j.therap.2024.04.002_bib0165","series-title":"European Drug Report 2022: Trends and Developments","year":"2022"},{"key":"10.1016\/j.therap.2024.04.002_bib0170","series-title":"Opioids: health and social responses","year":"2021"},{"key":"10.1016\/j.therap.2024.04.002_bib0175","series-title":"Tableau de bord \u201cTraitements de substitution aux opioides\u201d Mise \u00e0 jour septembre 2020. Observatoire fran\u00e7ais des drogues et des toxicomanies (OFDT)","first-page":"21","author":"Brisacier","year":"2020"},{"key":"10.1016\/j.therap.2024.04.002_bib0180","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s11920-007-0046-2","article-title":"Why buprenorphine is so successful in treating opiate addiction in France","volume":"9","author":"Fatseas","year":"2007","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.therap.2024.04.002_bib0185","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.addbeh.2004.04.019","article-title":"French general practitioners\u2019 prescribing high-dosage buprenorphine maintenance treatment: is the existing training (good) enough?","volume":"30","author":"Feroni","year":"2005","journal-title":"Addict Behav"},{"key":"10.1016\/j.therap.2024.04.002_bib0190","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0755-4982(04)72381-7","article-title":"Strat\u00e9gies th\u00e9rapeutiques pour les personnes d\u00e9pendantes des opiac\u00e9s: place des traitements de substitution","volume":"33","year":"2004","journal-title":"Presse Med"},{"key":"10.1016\/j.therap.2024.04.002_bib0195","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jama.285.1.39","article-title":"Deaths attributable to methadone vs buprenorphine in France","volume":"285","author":"Auriacombe","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2024.04.002_bib0200","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drugalcdep.2009.03.020","article-title":"Comparing overdose mortality associated with methadone and buprenorphine treatment","volume":"104","author":"Bell","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2024.04.002_bib0205","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000506630","article-title":"Primary care of opioid use disorder: the end of \u201cthe French model\u201d?","volume":"26","author":"Dupouy","year":"2020","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.therap.2024.04.002_bib0210","doi-asserted-by":"crossref","first-page":"108891","DOI":"10.1016\/j.jsat.2022.108891","article-title":"Prescribing buprenorphine for opioid use disorder in primary care: a survey of French general practitioners in the Sentinelles network","volume":"143","author":"L\u00e9pine","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.therap.2024.04.002_bib0215","unstructured":"R\u00e9seau Sentinelles. Bilan d\u2019activit\u00e9 2020. Sentiweb 2021. https:\/\/www.sentiweb.fr\/france\/fr\/?page=bilan. [Accessed 11 April 2024]."},{"key":"10.1016\/j.therap.2024.04.002_bib0220","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12963-014-0019-8","article-title":"Improving disease incidence estimates in primary care surveillance systems","volume":"12","author":"Souty","year":"2014","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.therap.2024.04.002_bib0225","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2515\/therapie\/2013022","article-title":"Opiate substitution treatment's cycles in a five-year followed-up cohort in ambulatory practice","volume":"68","author":"Dupouy","year":"2013","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.04.002_bib0230","unstructured":"Direction de la recherche, des \u00e9tudes, de l\u2019\u00e9valuation et des statistiques. D\u00e9mographie des professionnels de sant\u00e9. https:\/\/drees.shinyapps.io\/demographie-ps\/. [Accessed 11 April 2024]."},{"key":"10.1016\/j.therap.2024.04.002_bib0235","series-title":"Initiation et suivi du traitement substitutif de la pharmacod\u00e9pendance majeure aux opiac\u00e9s par bupr\u00e9norphine haut dosage","year":"2011"},{"key":"10.1016\/j.therap.2024.04.002_bib0240","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1080\/14656566.2017.1409722","article-title":"Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus","volume":"18","author":"Dematteis","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.therap.2024.04.002_bib0245","first-page":"9","article-title":"Treatment practices and perceived challenges for European physicians treating opioid dependence","volume":"12","author":"Bacha","year":"2010","journal-title":"Heroin Addict Relat Clin Probl"},{"key":"10.1016\/j.therap.2024.04.002_bib0250","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1360-0443.1998.9344753.x","article-title":"Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial","volume":"93","author":"Ling","year":"1998","journal-title":"Addiction"},{"key":"10.1016\/j.therap.2024.04.002_bib0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-017-1415-y","article-title":"Polydrug abuse among opioid maintenance treatment patients is related to inadequate dose of maintenance treatment medicine","volume":"17","author":"Heikman","year":"2017","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.therap.2024.04.002_bib0260","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.japh.2022.08.027","article-title":"Understanding the role of community pharmacies in current medication for opioid use disorder care practices","volume":"63","author":"Comanici","year":"2023","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.therap.2024.04.002_bib0265","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.japh.2022.08.017","article-title":"Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: a national survey of community-based pharmacists","volume":"63","author":"Hill","year":"2023","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.therap.2024.04.002_bib0270","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/IJGM.S61014","article-title":"The current status of opioid maintenance treatment in France: a survey of physicians, patients, and out-of-treatment opioid users","volume":"7","author":"Benyamina","year":"2014","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.therap.2024.04.002_bib0275","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.drugalcdep.2018.03.033","article-title":"Are patients\u2019 pejorative representations of buprenorphine associated with their level of addiction and of misuse?","volume":"188","author":"Vanderkam","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2024.04.002_bib0280","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.3390\/ijerph18041425","article-title":"What differs between patients under methadone and under buprenorphine for opioid use disorder (OUD) in daily clinical practice in France? A Short report","volume":"18","author":"Guillou-Landreat","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.therap.2024.04.002_bib0285","series-title":"Les centres de soins, d\u2019accompagnement et de pr\u00e9vention en addictologie en 2016","author":"Palle","year":"2018"},{"key":"10.1016\/j.therap.2024.04.002_bib0290","doi-asserted-by":"crossref","first-page":"628","DOI":"10.7326\/M18-1652","article-title":"The next stage of buprenorphine care for opioid use disorder","volume":"169","author":"Martin","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.therap.2024.04.002_bib0295","series-title":"Les traitements de substitution vus par les patients: quels sont les enseignements de leur exp\u00e9rience?","author":"Langlois","year":"2013"},{"key":"10.1016\/j.therap.2024.04.002_bib0300","series-title":"Alcohol, tobacco, drugs, screens: National plan for mobilisation against addictions 2018\u20132022.","year":"2018"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724000441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724000441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T13:54:58Z","timestamp":1732370098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595724000441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0040595724000441"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2024.04.002","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GPs\u2019 practices when prescribing buprenorphine in primary care: A survey among the Sentinelles network","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2024.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}